Drugs Containing Excipient (Inactive Ingredient) BUTYLATED HYDROXYANISOLE

Branded drugs containing BUTYLATED HYDROXYANISOLE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	BUTYLATED HYDROXYANISOLE
Merck Sharp & Dohme Corp	ZOCOR	simvastatin	0006-0543	BUTYLATED HYDROXYANISOLE
Allergan Inc	TAZORAC	tazarotene	0023-8335	BUTYLATED HYDROXYANISOLE

Generic drugs containing BUTYLATED HYDROXYANISOLE excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme LLC	ivermectin	0006-0032	BUTYLATED HYDROXYANISOLE
Merck Sharp & Dohme Corp	simvastatin	0006-0543	BUTYLATED HYDROXYANISOLE
Allergan Inc	tazarotene	0023-8335	BUTYLATED HYDROXYANISOLE

Butylated Hydroxyanisole Pharmaceutical Excipient Market: Market Dynamics, Regulation, Suppliers, and Financial Trajectory

Last updated: August 28, 2026

Butylated hydroxyanisole, commonly called BHA, is a low-volume, mature pharmaceutical excipient used primarily as an antioxidant in lipid-containing formulations. Its commercial value is driven by formulation protection, regulatory acceptance, and supply reliability rather than exclusivity or high unit pricing. The market has limited transparency because BHA is sold across pharmaceutical, food, animal-nutrition, cosmetic, and industrial channels, with suppliers rarely reporting excipient revenue separately.

BHA’s financial trajectory is likely to remain stable to modestly growing in pharmaceutical applications. Volume growth is constrained by substitution toward tocopherols, ascorbyl palmitate, propyl gallate, and other antioxidant systems, while demand remains supported by soft-gel capsules, oily oral products, topical formulations, and moisture- or oxygen-sensitive active ingredients.

What is butylated hydroxyanisole and how is it used in pharmaceuticals?

Butylated hydroxyanisole is a synthetic phenolic antioxidant identified by CAS RN 25013-16-5. Commercial BHA is generally a mixture of 2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole isomers.

In pharmaceutical formulations, BHA is used to:

• Reduce oxidation of active pharmaceutical ingredients.
• Protect unsaturated oils and lipid excipients.
• Improve stability of soft gelatin capsules.
• Limit rancidity in oral, topical, and veterinary products.
• Support shelf-life requirements where oxygen exposure is a degradation pathway.

BHA is normally used at low concentrations. Its economic value comes from preventing product degradation, not from contributing therapeutic activity. The excipient is therefore selected during formulation development based on compatibility, antioxidant performance, sensory impact, toxicology, and regulatory status.

Typical applications include lipid-based oral dosage forms, ointments, creams, capsules, nutritional products, and veterinary formulations. The excipient is less central to conventional immediate-release tablets that do not contain oxidation-sensitive ingredients.

How large is the pharmaceutical BHA market?

No authoritative public source reports a standalone global market size for pharmaceutical-grade BHA. Available market reports generally combine BHA with BHT, propyl gallate, tocopherols, or the broader antioxidants category. They also combine pharmaceutical demand with food, cosmetics, animal feed, and industrial applications.

The pharmaceutical segment is likely smaller than the food-preservation segment because BHA is used at low dosage and because pharmaceutical companies often have multiple antioxidant alternatives. The market is best characterized as a mature specialty-ingredient segment with:

Market characteristic	Assessment
Product maturity	Mature commodity excipient
Pharmaceutical growth	Low single-digit or lower in volume, subject to formulation trends
Pricing power	Limited for standard grades; higher for qualified, compendial, and documentation-heavy supply
Demand concentration	Distributed across many finished products and manufacturers
Main demand drivers	Soft gels, lipid formulations, topical products, veterinary medicines
Main restraints	Substitution, regulatory scrutiny, customer reformulation, low dosage levels
Competitive basis	Purity, consistency, documentation, delivery reliability, and price
Patent protection	No meaningful current composition or use exclusivity identified for BHA itself

The commercial market is less exposed to blockbuster-product cycles than an active pharmaceutical ingredient market. A supplier’s revenue depends more on customer retention, qualification status, regional distribution, and cross-sector demand than on one branded drug.

What drives the financial trajectory for pharmaceutical-grade BHA?

The financial outlook is tied to four operating variables: production cost, regulatory compliance, demand from lipid formulations, and substitution risk.

Raw materials and manufacturing economics

BHA is manufactured through aromatic ether chemistry involving methoxyphenol intermediates and tert-butylation chemistry. Cost exposure includes:

• Methoxyphenol feedstocks.
• Isobutylene or tert-butyl alcohol derivatives.
• Energy and solvent costs.
• Environmental controls.
• Batch testing and impurity management.
• Packaging and hazardous-material logistics.

Because BHA is a mature chemical, manufacturing know-how is broadly available. This limits structural margins unless a supplier has scale, regional cost advantages, or a differentiated pharmaceutical-quality documentation package.

Pharmaceutical qualification

A pharmaceutical customer usually values more than chemical identity. Qualification can require:

• Compendial compliance.
• Identity and assay testing.
• Residual-solvent controls.
• Elemental-impurity information.
• Genotoxic impurity assessment.
• Stability data.
• Change-control commitments.
• Audit rights and supply-continuity plans.
• Certificates of analysis and regulatory support files.

These requirements create switching costs. A low-cost supplier may not displace an incumbent immediately because a change can trigger formulation assessment, stability work, supplier qualification, and regulatory filings.

Formulation demand

BHA demand is strongest where the formulation contains oxidation-sensitive oils or active ingredients. Growth in lipid-based delivery systems can support demand, although newer systems often rely on mixed antioxidant packages or oxygen-control technologies.

Soft-gel products are a significant demand category because the fill material can contain vegetable oils, medium-chain triglycerides, fish oils, or other oxidation-sensitive components. Veterinary and animal-health products also provide recurring demand, particularly for oil-based formulations.

Which companies supply pharmaceutical-grade BHA?

The supply chain includes chemical manufacturers, specialty excipient distributors, laboratory suppliers, and regional pharmaceutical raw-material traders. Public disclosures do not consistently separate BHA production from distribution.

Known commercial channels include:

Supplier type	Examples of market role
Specialty chemical producers	Manufacture BHA or sell it through regional industrial and food-ingredient channels
Pharmaceutical excipient distributors	Supply compendial material, documentation, and regional inventory
Laboratory and small-volume suppliers	Provide development quantities and analytical standards
Contract manufacturers	Produce or package material under customer-specific quality arrangements

Merck/Sigma-Aldrich, Spectrum Chemical, and other laboratory or specialty suppliers list BHA products, but product availability does not by itself establish manufacturing ownership. Pharmaceutical buyers should distinguish between the original manufacturer, repackager, distributor, and regulatory-support provider.

The competitive market is fragmented. No single BHA supplier has publicly established dominant global pharmaceutical market share. Large chemical companies may have greater procurement and manufacturing scale, while specialist distributors can compete through inventory, regulatory support, and customer service.

What is the regulatory status of BHA as a pharmaceutical excipient?

BHA has a long regulatory history, but acceptance differs by jurisdiction and application.

United States

BHA is recognized for specified uses in food under 21 C.F.R. § 172.110. The U.S. Food and Drug Administration also maintains inactive-ingredient information for approved drug products through the Inactive Ingredient Database, although inclusion in a specific product does not create universal approval for all routes, strengths, or dosage forms.[1][2]

For pharmaceutical use, the relevant question is whether the proposed concentration, route of administration, and dosage form are supported by FDA precedent or require additional justification. A formulation sponsor must assess the applicable inactive-ingredient precedent rather than rely only on food-use status.

European Union

BHA is identified as food additive E320. Food authorization and pharmaceutical excipient acceptability are separate regulatory questions. European pharmaceutical manufacturers generally evaluate BHA under the applicable medicinal-product quality framework, pharmacopoeial requirements, toxicological data, and product-specific risk assessment.

Pharmacopoeial position

BHA has been included in recognized pharmaceutical and chemical quality standards. Buyers should confirm the current edition and exact monograph requirements for the jurisdiction in which the product is manufactured, released, or marketed. The United States Pharmacopeia-National Formulary and other compendia may impose identity, assay, impurity, and performance requirements that exceed a general industrial-grade specification.

What are the safety and regulatory risks for BHA?

BHA faces more regulatory scrutiny than many inert formulation ingredients because it is also used as a food antioxidant and has been evaluated for long-term exposure.

The Joint FAO/WHO Expert Committee on Food Additives established a group acceptable daily intake of 0-0.5 mg/kg body weight for BHA, expressed as BHA equivalents.[3] The European Food Safety Authority has separately evaluated BHA exposure and toxicology in the context of food additive use.[4]

Key pharmaceutical risk factors include:

• Cumulative exposure from food, cosmetics, supplements, and medicines.
• Route-specific tolerability.
• Pediatric exposure.
• Chronic-use products.
• High-dose or repeated-dose formulations.
• Potential regulatory preference for alternative antioxidants.
• Labeling and excipient-information requirements.

These issues do not eliminate BHA from pharmaceutical use. They can, however, increase the burden of justification for chronic oral products, pediatric medicines, and products with substantial daily excipient exposure.

What formulations are protected by BHA, and are there formulation patents?

BHA itself is not generally protected by an active pharmaceutical patent estate. Its composition is old, and no meaningful market exclusivity attaches to ordinary BHA use as an antioxidant.

Patent protection may exist at the finished-product level for:

• Specific combinations of an active ingredient and BHA.
• Antioxidant systems with defined ratios.
• Lipid vehicles containing BHA and other stabilizers.
• Soft-gel compositions.
• Topical or ophthalmic formulations.
• Manufacturing processes that control oxidation or impurity formation.
• Extended-release formulations using BHA-containing matrices.

Those rights would protect a particular formulation or manufacturing method, not BHA as a chemical excipient. Patent analysis must therefore be conducted against the finished drug, formulation owner, and jurisdiction.

Are there Paragraph IV challenges involving BHA?

No material Paragraph IV litigation is associated with BHA as a standalone excipient. Paragraph IV certifications apply to abbreviated new drug applications challenging listed drug patents, not to the ordinary sale of a non-active excipient.

A generic drug containing BHA could face Paragraph IV litigation over the active ingredient, dosage form, method of use, or formulation. The challenge would not normally arise because the product contains BHA.

Does BHA have Orange Book listings?

BHA is not an active pharmaceutical ingredient with its own Orange Book listing. It can appear as an inactive ingredient in approved drug products, but inactive-ingredient presence does not create Orange Book exclusivity or a standalone patent listing.

How strong is the patent estate for pharmaceutical BHA?

The BHA patent estate is weak from a market-exclusivity perspective.

Patent category	Commercial relevance for BHA
Composition-of-matter patents	Expired or commercially irrelevant
Basic antioxidant-use patents	Generally expired or nonexclusive
Manufacturing-process patents	Possible in narrow cases, with limited market impact
Finished-drug formulation patents	Potentially relevant to specific products
Trade secrets	Possible for process efficiency, impurity control, and crystallization
Regulatory exclusivity	None for BHA as a standalone excipient
Orange Book protection	None as a standalone ingredient

The principal barriers are qualification, quality systems, supply continuity, and regulatory documentation. These barriers can protect customer relationships without producing legal exclusivity.

How does BHA compare with alternative pharmaceutical antioxidants?

BHA competes with both synthetic and naturally derived antioxidants.

Antioxidant	Relative strengths	Relative limitations
BHA	Effective at low concentration; established supply; compatible with many lipid systems	Regulatory scrutiny; consumer preference concerns; substitution risk
BHT	Strong antioxidant performance; often paired with BHA	Similar regulatory and perception issues
Tocopherols	Natural-positioning advantage; useful in oils	Higher cost; variable potency; formulation compatibility limits
Ascorbyl palmitate	Lipid-compatible; useful in combination systems	Can require formulation optimization and has narrower use conditions
Propyl gallate	Effective synthetic antioxidant; established use	Compatibility, color, and regulatory considerations
Sodium metabisulfite	Effective in selected aqueous systems	Sulfite sensitivity and limited suitability for lipid formulations
Chelating agents	Improve performance by controlling catalytic metals	Usually require combination with a primary antioxidant

BHA remains competitive where cost, potency, and established regulatory precedent outweigh demand for naturally derived ingredients. Tocopherols and mixed antioxidant systems are the most credible substitution threats in products marketed around clean-label or naturally sourced excipients.

What geographic factors affect BHA supply?

BHA supply is exposed to regional manufacturing concentration, import dependence, and chemical compliance requirements. Pharmaceutical customers often require dual sourcing because a disruption at one production site can affect multiple dosage forms.

Regional market considerations include:

• North America: Strong documentation expectations and FDA-related inactive-ingredient review.
• Europe: Emphasis on chemical compliance, excipient quality, and food-additive scrutiny.
• India: Large pharmaceutical manufacturing base and strong demand for cost-efficient excipients.
• China: Important chemical manufacturing and export capacity, with supplier qualification and consistency as major buyer concerns.
• Japan and South Korea: High quality and documentation standards, with demand from sophisticated formulation manufacturers.
• Latin America and other emerging markets: More price-sensitive procurement, often dependent on distributors and imports.

Import controls, REACH obligations, customs classification, transport restrictions, and local GMP expectations can affect delivered cost more than the nominal BHA price.

What generic launch risks exist for drugs containing BHA?

BHA does not materially increase generic launch risk unless it is part of a protected formulation or a product-specific method of use. Generic applicants generally assess:

1. Whether BHA is present in the reference product.
2. Whether the same inactive ingredient and level can be used.
3. Whether the dosage form has a patent-protected antioxidant system.
4. Whether BHA affects bioequivalence, stability, dissolution, or release.
5. Whether the proposed formulation creates a new safety or labeling issue.

For conventional oral products, BHA is usually a manageable formulation component. For lipid-based, ophthalmic, topical, pediatric, or modified-release products, changing the antioxidant system may require more extensive development work.

What licensing deals and settlement agreements involve BHA?

No material licensing transaction or patent settlement centered on BHA as a standalone pharmaceutical excipient is publicly established. Licensing economics arise at the finished-drug level, where BHA may be one component of a formulation covered by a broader intellectual-property agreement.

A supplier may use quality agreements, preferred-supplier contracts, regional distribution arrangements, or customer-specific manufacturing agreements. These are commercial supply arrangements, not exclusivity rights over BHA.

What is the five-year financial outlook for pharmaceutical BHA?

The base case is stable demand with modest nominal revenue growth. The most likely trajectory is:

Period	Expected market condition
Near term	Stable pharmaceutical consumption; periodic price pressure from raw materials and logistics
Medium term	Low-volume growth from lipid formulations and emerging-market manufacturing
Longer term	Continued substitution pressure from tocopherols and blended antioxidant systems

Revenue growth is more likely to come from price, grade upgrades, and geographic expansion than from large unit-volume increases. Pharmaceutical-grade material can command a premium over food or industrial grades because of testing, traceability, qualification, and regulatory support. That premium may narrow as more suppliers achieve acceptable documentation standards.

The largest downside risk is reformulation. A major customer migration from BHA to tocopherols or a blended antioxidant package can permanently reduce demand. The largest upside opportunity is increased use of lipid-based delivery systems, where oxidation control is essential and BHA remains technically effective.

Key Takeaways

• BHA is a mature, low-volume pharmaceutical excipient rather than a high-growth specialty drug ingredient.
• Public data does not support a reliable standalone global pharmaceutical BHA market-size estimate.
• Pharmaceutical demand is concentrated in soft gels, lipid formulations, topical products, veterinary medicines, and oxidation-sensitive products.
• BHA has no meaningful standalone patent, Orange Book, Paragraph IV, or regulatory exclusivity position.
• Supplier differentiation depends on quality documentation, compendial compliance, qualification support, and supply continuity.
• Regulatory scrutiny and substitution by tocopherols or other antioxidant systems are the main structural risks.
• The financial outlook is stable to modestly growing, with pricing and grade premiums more important than volume expansion.
• Finished-drug formulation patents can matter, but they protect specific products rather than BHA itself.

FAQs about pharmaceutical-grade butylated hydroxyanisole

Is BHA the same as BHT in pharmaceutical formulations?

No. BHA is butylated hydroxyanisole, while BHT is butylated hydroxytoluene. Both are synthetic phenolic antioxidants, but they have different chemical structures, specifications, compatibility profiles, and regulatory records.

Can pharmaceutical companies replace BHA with vitamin E?

Sometimes. Tocopherols can replace or supplement BHA in oil-based formulations, but the substitution requires compatibility, stability, dose, packaging, and regulatory evaluation. A direct one-for-one replacement is not assured.

Is BHA allowed in injectable medicines?

BHA is not a general-purpose injectable excipient. Use in parenteral products would require route-specific safety justification, applicable regulatory precedent, and product-specific toxicological assessment.

Does BHA affect drug bioavailability?

It can affect product performance indirectly if it changes lipid oxidation, drug solubility, vehicle stability, or release behavior. The impact is formulation-specific and must be evaluated through stability and performance testing.

What is the main procurement risk for pharmaceutical BHA?

The main procurement risk is not patent loss. It is supply interruption, inconsistent quality, or loss of qualified-source status. Pharmaceutical buyers typically mitigate that risk through dual sourcing, change-control provisions, and supplier audits.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. § 172.110: Butylated hydroxyanisole. https://www.ecfr.gov/current/title-21/section-172.110
3. Joint FAO/WHO Expert Committee on Food Additives. (n.d.). Evaluations of the Joint FAO/WHO Expert Committee on Food Additives: Butylated hydroxyanisole. World Health Organization. https://apps.who.int/food-additives-contaminants-jecfa-database/
4. European Food Safety Authority. (2017). Re-evaluation of butylated hydroxyanisole-BHA (E 320) as a food additive. EFSA Journal, 15(12), 5094. https://doi.org/10.2903/j.efsa.2017.5094
5. U.S. Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. https://www.usp.org
6. European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition